Oral vs injectable GLP-1s

The basic problem

Peptides are notoriously difficult to deliver orally. They are degraded by stomach acid and digestive enzymes, and they cross the gut wall poorly. The first generation of GLP-1 receptor agonists were therefore all injected.

Two engineering paths have produced oral GLP-1 options:

1. Peptide + absorption enhancer — the Rybelsus approach.
2. Small molecule (non-peptide) GLP-1 receptor agonists — orforglipron, danuglipron, and the broader emerging class.

Path 1: Oral peptide GLP-1 — Rybelsus

Rybelsus is oral semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), an absorption enhancer that protects semaglutide from gastric degradation and promotes its uptake across the gastric mucosa.

The trade-off is real-world adherence. To achieve consistent absorption, Rybelsus must be taken:

• On an empty stomach, after at least an overnight fast
• With no more than 4 oz of plain water
• Followed by no food or other medications for at least 30 minutes

Bioavailability is still low (roughly 0.4–1%), and effective oral doses must therefore be much higher than equivalent subcutaneous doses. Adherence to the timing requirements is part of why oral peptide GLP-1s have not displaced weekly injectables despite being available.

Path 2: Small-molecule non-peptide GLP-1 — orforglipron and friends

Small-molecule GLP-1 receptor agonists activate the same receptor but through a different binding mode that small molecules can access. Their advantages over Rybelsus are substantial:

• Food and water-timing flexibility. Orforglipron has demonstrated absorption that is largely independent of food / water timing — a major real-world adherence advantage.
• No absorption-enhancer co-formulation needed.
• Standard manufacturing economics for small molecules vs. recombinant peptide production.

The challenge has been safety stewardship. Pfizer's danuglipron program was discontinued in April 2025 following a hepatic safety signal in a single trial participant. Lotiglipron, an earlier Pfizer candidate, had been discontinued earlier for hepatic enzyme elevations. Orforglipron's Phase 3 hepatic profile is being closely watched as the leading candidate in the class.

Efficacy: oral vs injectable

Phase 2 data on orforglipron showed weight loss in obesity at 36 weeks of ~9–15% across doses, with placebo at ~2.3%. Phase 3 readouts (ACHIEVE, ATTAIN) are extending the picture. While direct head-to-head trials with weekly injectables are limited, the magnitude is in the same range as semaglutide 2.4 mg, somewhat below tirzepatide 15 mg.

Rybelsus efficacy is below subcutaneous semaglutide at equivalent therapeutic doses, partly reflecting bioavailability constraints.

Side effects

The GI side-effect profile of oral GLP-1s mirrors the injectable class — nausea, diarrhea, vomiting, constipation — at rates that scale with dose and titration speed. The hepatic signal seen with some small-molecule candidates is a class-specific consideration that does not apply to peptide GLP-1s.

Practical implications

• For patients who dislike or cannot use injections, oral options are a meaningful alternative — though Rybelsus's strict timing requirements are a real adherence barrier and small-molecule oral GLP-1s have not yet been approved as of early 2026.
• For patients seeking maximum weight loss, weekly injectables (especially tirzepatide) currently produce larger reductions than current oral options.
• For payers and health systems, oral options change cost-of-goods, distribution, and potentially access; the 2025–2027 readouts in this space could meaningfully expand the GLP-1 user base.

Bottom line

Oral GLP-1s are the next major access frontier for the class. Rybelsus exists today but with adherence barriers; orforglipron is the most credible candidate for a true once-daily oral GLP-1 with practical real-world dosing. The hepatic safety stewardship of the small-molecule oral class is the area to watch as Phase 3 programs read out.